Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:EXAS News 20 November 2025 - 2 February 2026

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
···
Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott Laboratories shares rose 0.3% to $106.34 Thursday after a broker upgrade, following sharp losses from missed revenue and a cautious outlook last week. The stock touched a 52-week low of $105.27. Abbott plans to acquire Exact Sciences for $105 per share, with a shareholder vote set for Feb. 20. The company declared a $0.63 quarterly dividend, payable Feb. 13.
29 January 2026
··
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

NEW YORK, December 30, 2025, 19:51 ET — After-hours Abbott Laboratories (ABT.N) shares rose 0.97% to $125.78 in Tuesday’s regular session and held steady in after-hours trading. ABT quote The move lands as investors reprice 2026 catalysts for large-cap healthcare, where product cycles and deal timelines can matter more than day-to-day macro noise. Abbott has two big threads in play: a planned push deeper into cancer screening through a major acquisition and a newly cleared heart-rhythm device in a fast-developing market. Both can influence revenue mix and margins, which feed directly into valuation. In the broader tape, U.S. stocks ended
31 December 2025
·
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences Corporation (NASDAQ: EXAS) has turned into one of the most closely watched healthcare stocks heading into December 2025, thanks to a blockbuster takeover agreement with Abbott Laboratories, strong Q3 results, and a rapid share‑price rally that has pushed EXAS to all‑time highs. As of mid‑day on December 1, 2025, the stock trades around $101 per share, just below the agreed $105 per‑share cash buyout price. Exact Sciences Investor Relations+1 Below is a deep dive into the latest news, earnings, analyst forecasts, and key risks around Exact Sciences stock as of December 1, 2025. Exact Sciences Stock Today: Trading
1 December 2025
··
Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences Corporation (NASDAQ: EXAS) is trading near record highs as Wall Street shifts to “Hold,” merger-arb funds move in and shareholder lawyers start circling Abbott’s $21 billion bid. Exact Sciences Stock Price Snapshot for 25 November 2025 On Tuesday, 25 November 2025, Exact Sciences stock is trading around $101 per share, hovering just below its all‑time and 52‑week high near $102.ChartMill+1 That puts EXAS: At this point, EXAS is behaving less like a typical growth stock and more like a merger‑arbitrage trade: most of the upside is capped by the announced cash offer, while the remaining discount compensates investors
25 November 2025
··
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Dateline: November 24, 2025 Exact Sciences Corporation (NASDAQ: EXAS) stock is trading calmly near its takeover price today as Wall Street digests a flood of fresh analyst calls, legal scrutiny and local reaction to Abbott Laboratories’ multi‑billion‑dollar bid for the cancer‑diagnostics specialist. With shares hovering around $101 this afternoon and a cash offer on the table at $105 per share, Exact Sciences has effectively shifted from a high‑growth story to a merger‑arbitrage situation — but there’s still plenty happening around the name on November 24, 2025. Exact Sciences Investor Relations+1 Key takeaways for EXAS stock on November 24, 2025 Exact
24 November 2025
··
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion in equity and roughly $23 billion including debt. Reuters+2PR Newswire+2 The move marks Abbott’s largest acquisition in nearly a decade and one of the biggest healthcare deals of 2025, instantly positioning the company as a heavyweight in cancer screening and precision oncology diagnostics — markets it has largely approached from the sidelines until now. Reuters+1 As of mid‑afternoon trading, ABT
20 November 2025
··
Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal in nearly a decade. Abbott MediaRoom+2Reuters+2 The transaction gives Abbott an immediate leadership position in fast‑growing cancer screening and precision oncology diagnostics, anchored by Exact Sciences’ flagship tests Cologuard and Oncotype DX, plus its new multi‑cancer blood test Cancerguard. Abbott MediaRoom+2investor.exactsciences.com+2 Deal Terms: $105 per Share and a $23 Billion Enterprise Value Under the definitive agreement announced today, Abbott will
20 November 2025
··

Stock Market Today

Silver price rebound masks fresh stress after CME lifts margins again

Silver price rebound masks fresh stress after CME lifts margins again

7 February 2026
Spot silver surged 8.6% to $77.33 an ounce Friday after dropping below $65, but still lost over 8.7% for the week. CME Group raised margin requirements for COMEX silver futures to 18% from 15%, effective after Feb. 6. China’s UBS SDIC Silver Futures Fund hit its 10% down limit for a fifth session. Traders await key U.S. jobs and inflation data next week.
Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

7 February 2026
China’s central bank raised gold reserves for a 15th month in January, reaching 74.19 million ounces worth $369.58 billion. Gold prices swung sharply, hitting a record near $5,600 before dropping to $4,403.24. CME Group hiked COMEX gold futures margins to 9% after recent volatility. U.S. jobs and inflation data are due next week after a delay.
Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company forecast 2026 capital spending would jump to $200 billion, up more than 50% from 2025. The drop came as the Dow closed above 50,000 for the first time. Amazon reported fourth-quarter net sales up 14% to $213.4 billion and operating income at $25 billion. Trading in Amazon was volatile, with 179 million shares changing hands.
Go toTop